Help shape the future for millions of Americans at risk or living with lung cancer. Make your voice heard demanding vital federal funding for lung cancer research. This year we’re requesting $20 million to increase the Lung Cancer Research [...]
At GO2 for Lung Cancer we believe when social injustice rules whether through stigma, unequal access to healthcare, or violent and discriminatory actions, no one wins. We must stand together now, change this wrong, and unite as a nation [...]
On May 29, 2020, the Food and Drug Administration (FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in EGFR called exon [...]
This past week marked a grim milestone in the United States, as we officially surpassed 100,000 deaths from COVID-19. Our groups continue to recommend that the lung cancer community adhere to best practices to limit exposure, including wearing masks/face [...]
Now, more than ever, we must raise our collective voices to protect vital federal research funding for lung cancer. Help us reach lawmakers on Capitol Hill to urge them to fully fund the Lung Cancer Research Program. We’re holding [...]
On May 26, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab), Yervoy (ipilimumab), and two cycles of platinum-doublet chemotherapy for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having [...]
On May 22, 2020, the Food and Drug Administration (FDA) approved Alunbrig (brigatinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in ALK. The FDA based their approval on the results [...]
By Jennifer C. King, PhD, Chief Scientific Officer I’m an optimist at heart -- to the point where my tween daughter just rolls her eyes at me whenever I tell her to have a more positive attitude. Consequently, while [...]
As different states are relaxing shelter-at-home orders and businesses are planning to re-open, it is important to understand the true extent of COVID-19 infections: both active infections (patients who are currently infected) and past infections (patients who were infected [...]